Evaluating patient wellbeing following tildrakizumab treatment: the POSITIVE study
During the EADV Congress 2023 and AAD Annual Meeting 2024, results from the POSITIVE study, which evaluated wellbeing in psoriasis patients treated with tildrakizumab were presented [1,2]. This is the first study that has evaluated wellbeing in a robust way in a prospective interventional psoriasis study.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
